ES2150941T3 - Aminas biciclicas-heterociclicas eficaces farmaceuticamente. - Google Patents

Aminas biciclicas-heterociclicas eficaces farmaceuticamente.

Info

Publication number
ES2150941T3
ES2150941T3 ES93908303T ES93908303T ES2150941T3 ES 2150941 T3 ES2150941 T3 ES 2150941T3 ES 93908303 T ES93908303 T ES 93908303T ES 93908303 T ES93908303 T ES 93908303T ES 2150941 T3 ES2150941 T3 ES 2150941T3
Authority
ES
Spain
Prior art keywords
heterociclic
amines
pharmaceutically effective
bicycle
effective bicycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908303T
Other languages
English (en)
Inventor
Donald E Ayer
Gordon L Bundy
Eric Jon Jacobsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2150941T3 publication Critical patent/ES2150941T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTAN LOS AMINOS BICICLICOS-HETEROCICLICOS FARMACOLOGICAMENTE ACTIVOS (XXX), DONDE W1 ES N= O -CH=; W3 ES -N= O -CH=; W5 ES -.N= O -CR5ANDO TANTO W1 COMO W3 SEAN -N=, LOS COMPUESTOS SON UTILES COMO PRODUCTOS FARMACEUTICOS EN EL TRATAMIENTO DE LESIONES DE CABEZA LEVES Y/O DE MODERADAS A SEVERAS, HEMORRAGIAS SUBARACNOIDES Y EL SUBSECUENTE CHOQUE ISQUEMICO, EL ASMA Y LA REDUCCION DE LA FORMACION/SECRECION DE MUCOSIDAD EN EL PULMON Y OTRAS ENFERMEDADES Y LESIONES.
ES93908303T 1992-04-03 1993-03-16 Aminas biciclicas-heterociclicas eficaces farmaceuticamente. Expired - Lifetime ES2150941T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86364692A 1992-04-03 1992-04-03

Publications (1)

Publication Number Publication Date
ES2150941T3 true ES2150941T3 (es) 2000-12-16

Family

ID=25341481

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908303T Expired - Lifetime ES2150941T3 (es) 1992-04-03 1993-03-16 Aminas biciclicas-heterociclicas eficaces farmaceuticamente.

Country Status (21)

Country Link
EP (1) EP0633886B1 (es)
JP (1) JPH08502721A (es)
KR (1) KR100284473B1 (es)
AT (1) ATE197051T1 (es)
AU (1) AU675932B2 (es)
CA (1) CA2130937A1 (es)
CZ (1) CZ236494A3 (es)
DE (1) DE69329574T2 (es)
DK (1) DK0633886T3 (es)
ES (1) ES2150941T3 (es)
FI (1) FI944602A7 (es)
GR (1) GR3035188T3 (es)
HU (1) HUT70954A (es)
LV (1) LV12794B (es)
MX (1) MX9301847A (es)
NO (1) NO303542B1 (es)
PL (2) PL175347B1 (es)
PT (1) PT633886E (es)
RU (1) RU2103272C1 (es)
SK (1) SK119194A3 (es)
WO (1) WO1993020078A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304519A (en) * 1995-03-02 2000-01-28 Upjohn Co Pydrimido[4,5-b]indoles
US5753635A (en) * 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
KR20000057137A (ko) 1996-11-19 2000-09-15 스티븐 엠. 오드레 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
WO1998024453A1 (en) * 1996-12-05 1998-06-11 Nippon Shinyaku Co., Ltd. Remedies for myelopathy
SI0964865T1 (en) * 1997-01-08 2003-08-31 Pharmacia & Upjohn Company Pharmaceutically active tricyclic amines
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB2331988B (en) 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP4611524B2 (ja) * 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1115731A2 (de) * 1998-09-04 2001-07-18 Byk Gulden Lomberg Chemische Fabrik GmbH Neue pyranosen
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
HK1050319B (en) * 1999-12-02 2007-04-04 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
CO5271715A1 (es) 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
ATE431349T1 (de) * 2000-07-11 2009-05-15 Pharma Mar Sa Variolinderivate als antikrebsmittel
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
SE0003795D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
DK1450811T3 (da) 2001-11-30 2010-02-15 Osi Pharm Inc Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
CN1620294A (zh) 2001-12-20 2005-05-25 Osi药物公司 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
US20070185217A1 (en) 2003-12-23 2007-08-09 Abraxis Bioscience, Inc. Propofol analogs, process for their preparation, and methods of use
PL381247A1 (pl) * 2004-03-04 2007-05-14 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
AU2005264998A1 (en) 2004-06-17 2006-01-26 Wyeth The present invention relates to methods of making Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists
KR20070027584A (ko) 2004-06-17 2007-03-09 와이어쓰 고나도트로핀 방출 호르몬 수용체 길항제
ES2315877T3 (es) 2004-06-18 2009-04-01 Biolipox Ab Indoles utiles en el tratamiento de inflamaciones.
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
CN101142185A (zh) 2005-01-19 2008-03-12 比奥里波克斯公司 用于炎症治疗的吲哚
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
FR2884824B1 (fr) * 2005-04-20 2007-07-13 Sanofi Aventis Sa Derives de 1h-pyrimido[4,5-b]indole, leur preparation et leur application en therapeutique
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
KR100749216B1 (ko) * 2006-08-30 2007-08-13 위아 주식회사 4륜구동차량용 부변속기
CA2668959A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
ES2424977T3 (es) * 2007-08-08 2013-10-10 Glaxosmithkline Intellectual Property Development Limited Derivados de 2-[(2-{fenilamino}-1H-pirrolo[2,3-D]pirimidin-4-il)amino]benzamida como inhibidores de IGF-1R para el tratamiento del cáncer
DK2178870T3 (en) * 2007-08-17 2018-10-22 Lg Chemical Ltd INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
CA2712701A1 (en) 2008-01-31 2009-08-06 Henning Steinhagen Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
AU2009314544C1 (en) * 2008-11-11 2015-11-12 Xcovery Holding Company Llc PI3K/mTOR kinase inhibitors
MY170236A (en) 2010-10-06 2019-07-11 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
MX343706B (es) 2011-01-31 2016-11-18 Novartis Ag Derivados heterocíclicos novedosos.
EP2686320B1 (en) 2011-03-15 2016-05-18 Merck Sharp & Dohme Corp. Tricyclic gyrase inhibitors
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
EP2807165B1 (en) 2012-01-27 2019-05-15 Université de Montréal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
SG11201607586UA (en) 2014-03-13 2016-10-28 Agency Science Tech & Res Fused pyrimidine-based hydroxamate derivatives
ES2849998T3 (es) * 2014-09-22 2021-08-24 National Health Res Inst Compuestos heterocíclicos y su uso
KR102278306B1 (ko) 2015-06-05 2021-07-15 헤마-퀘벡 조혈 줄기세포를 전구 세포로 배양 및/또는 분화시키는 방법 및 그의 용도
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
MX2020008265A (es) * 2018-02-16 2020-09-21 UCB Biopharma SRL Derivados farmaceuticos del anillo heterobiciclico 6,5.
SG11202106304RA (en) * 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
US20240150358A1 (en) * 2020-06-03 2024-05-09 Kineta, Inc. Purines and methods of their use
TW202216693A (zh) * 2020-06-26 2022-05-01 美商坦帕斯醫療公司 Trex1抑制劑及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
CA2065434C (en) * 1989-09-19 1999-11-30 Yasuji Sakuma Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and pharmaceutical preparation comprising the same as active ingredient

Also Published As

Publication number Publication date
DK0633886T3 (da) 2000-12-18
PL175327B1 (pl) 1998-12-31
SK119194A3 (en) 1995-05-10
AU3917493A (en) 1993-11-08
NO303542B1 (no) 1998-07-27
EP0633886A1 (en) 1995-01-18
MX9301847A (es) 1993-10-01
HUT70954A (en) 1995-11-28
GR3035188T3 (en) 2001-04-30
KR950700912A (ko) 1995-02-20
RU2103272C1 (ru) 1998-01-27
KR100284473B1 (ko) 2001-04-02
AU675932B2 (en) 1997-02-27
LV12794A (en) 2002-02-20
WO1993020078A1 (en) 1993-10-14
PL175347B1 (pl) 1998-12-31
ATE197051T1 (de) 2000-11-15
DE69329574D1 (de) 2000-11-23
CA2130937A1 (en) 1993-10-14
CZ236494A3 (en) 1994-12-15
NO943655L (no) 1994-12-05
FI944602A0 (fi) 1994-10-03
FI944602L (fi) 1994-10-03
NO943655D0 (no) 1994-09-30
PT633886E (pt) 2001-03-30
FI944602A7 (fi) 1994-10-03
LV12794B (lv) 2002-06-20
EP0633886B1 (en) 2000-10-18
RU94042466A (ru) 1996-07-20
DE69329574T2 (de) 2001-05-31
JPH08502721A (ja) 1996-03-26
HU9402829D0 (en) 1995-02-28

Similar Documents

Publication Publication Date Title
ES2150941T3 (es) Aminas biciclicas-heterociclicas eficaces farmaceuticamente.
ES2092460T1 (es) Composicion donadora de oxido nitrico y procedimiento para el tratamiento de trastornos anales.
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
DE69534150D1 (de) Präsynaptische Neurotoxine gegen Migränekopfschmerzen
SE8804629D0 (sv) New therapeutically active compounds
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
EP0706373A4 (en) TAXOL ENCLOSED IN LIPOSOMES AND METHOD OF USE
FI954130A0 (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
NO963850L (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
FR2680172B1 (fr) Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
FR2581382B1 (fr) Derives n-(quinolyl) glycinamides, leur procede de preparation et leur application therapeutique en tant que psychotropes
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE27813T1 (de) N-substituierte 1-(4'-alkylsulfonylphenyl)-2amino-1,3-propanediol-derivate.
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
FI98456B (fi) Menetelmä terapeuttisesti aktiivisten 1-piperidinyylialkanoyyliaryylisulfonamidijohdannaisten valmistamiseksi
DE3466981D1 (de) 1-(4'-alkylthiophenyl)-2-amino-1,3-propanediol n-substituted derivatives
NO177705C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive ascorbinsyrederivater
ATE247963T1 (de) Medikament zur behandlung von glaukoma und ischämischer retinopathie
DK164987C (da) Anvendelse af spergualin eller et farmaceutisk acceptabelt salt deraf til fremstilling af et laegemiddel med transplantationsimmunitetsinhiberende og antiallergisk aktivitet
RU92016567A (ru) Производные тетразола и антиаллергическая композиция
SE9901273D0 (sv) Novel compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633886

Country of ref document: ES